

DT05 Rec'd PCT/PTO

P 0 3 SEP 2002

Docket No. SWA4338P0090US
(WP/1801)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ray C.J. Chiu et al.

Serial No.: 10/089,710

Filed: April 1, 2002

-) Autologous Marrow Stem Cell (MSC)
-) Transplantation for Myocardial
-) Regeneration
-)
-) Group Art Unit: Not Known
-)
-) Examiner: Unassigned

RECEIVED

JAN 02 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

RECEIVED

NOV 05 2002

TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information of which they are aware which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56. While information provided in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. 1.56, the Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists, as defined in 37 C.F.R. 1.56.

37 CFR 1.8
CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service, as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on August 27, 2002.

Corinne Byk
Corinne Byk

A list of the patents and/or publications is set forth on the attached Form PTO-1449, and a copy of each of the items is supplied herewith.


This Information Disclosure Statement is not being submitted within three months of the filing date of the national application, but it is being filed before receipt of a First Office Action. Therefore, we believe no fee is due. If any additional fee might be required in connection with this matter, please charge our Deposit Account No. 23-0785.

Respectfully submitted,


WOOD, PHILLIPS, KATZ, CLARK & MORTIMER

Date: August 27, 2002

By


Martin L. Katz, Reg. No. 25,011

Citicorp Center, Suite 3800
500 West Madison Street
Chicago, IL 60661-2511
(312) 876-1800



✓	Robinson SW, Cho PW, Levitsky HI et al.: Arterial delivery of genetically labeled skeletal myobalsts to the murine heart: Long-term survival and phenotypic modification of implanted myoblasts. <i>Cell Transplantation</i> 5:77-91, 1996
✓	Taylor, D.A.; Atkins B.Z., Hungspreugs P., et al.: Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation. <i>Nat. Med.</i> 1998; 4:929-933
✓	Lichtman MD: The relationship of stromal cells to hemopoietic cells in marrow. In <i>Long Term Bone Marrow Culture</i> , pp. 57-96, DG Wright, JS Greenberger (eds), Alan R. Liss, New York, 1984
✓	Caplan AI: The mesengenic process. <i>Clinics Plast Surg</i> 1994;21:429-435
✓	Friedenstein A.J. et al. in <i>Exper. Hematol.</i> 1976; 4:276
✓	Pereira R.F., Halford K., O'Hara M.D. et al.: Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. <i>Proc. Natl. Acad. Sci.</i> 1995; 92:4857-4861
✓	Horwitz EM, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. <i>Nature Medicine</i> 5, 309-313, 1999
✓	Makino S. Fukuda K, Miyoshi S, et al.: Cardiomyocytes can be generated from marrow stromal cells <i>in vitro</i> . <i>J. Clin. Invest.</i> 1999; 103:697-705
✓	Connold A.L., Frischknecht R, Dimitrakos M, Vrbova G. The survival of embryonic cardiomyocytes transplanted into damaged host rat myocardium. <i>J Muscle Res Cell Motil</i> 1997;18:63-70
✓	Onifer SM, White LA, Whittemore SR, Holets VR. <i>In vitro</i> labeling strategies for identifying primary neural tissue and a neuronal cell line after transplantation in the CNS. <i>Cell Transplantation</i> 1993;2:131-149
✓	Singer JW, Charbond P, Keating A, Nemunaitis J, Raugi G, Wight TN, et al. Simian virus-40 transformed adherent cells from human long-term marrow cultures: Clone cells produced with "stromal" and hematopoietic characteristics. <i>Blood</i> 1987;70:464-474
✓	Shi BQ, Rafii S, Wu MHD, Wijelath ES, Yu C, Ishida A, et al. Evidence for circulating bone marrow-derived endothelial cells. <i>Blood</i> 1998;92:362-367
✓	Wakitani S, Saito T, Caplan A.I. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. <i>Muscle & Nerve</i> 1995;18:1417-1426
✓	Momparler RL, Laliberte J, Eliopoulos N, Beausejour C, Cournoyer D. Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside. <i>Anti-Cancer Drugs</i> 1996;7:266-274
✓	Nagy JJ, Li WE, Roy C, Doble BW, Gilchrist JS, Kardami E, Hertzberg EL. Selective monoclonal antibody recognition and cellular localization of an unphosphorylated form of connexin 43. <i>Exp. Cell Res.</i> 1997; 236:127 - 136
✓	Tomita S, et al. Autotransplanted mesenchymal stem cells improve function after a myocardial infarction. <i>Circulation</i> 1998; 98(suppl 17):ABS1036
✓	Prockpo D. et al. Marrow stromal cells for nonhematopoietic tissues. <i>Science</i> 1997; 276:71-74
✓	Bruder SP et al. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. <i>Journal of Cellular Biochemistry</i> 1994; 56(3):283-294
✓	Ferrari G et al. Muscle regeneration by bone marrow-derived myogenic progenitors. <i>Science</i> 1998; 279:1528-1530

RECEIVED

NOV 05 2002

TECH CENTER 1600/2900

	✓	Kessler PD et al. Myoblast cell grafting into heart muscle: cellular biology and potential applications. Annual review of Physiology 1999; 61:219-242
--	---	---

Examiner	Date considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



RECEIVED

NOV 05 2002

TECH CENTER 1600/2900

RECEIVED

JAN 02 2003

TECH CENTER 1600/2900



RECEIVED

JAN 02 2003

TECH CENTER 1600/2900 1 of 3

Form PTO-1449 (Rev.7-80)	U.S. Department of Commerce Patent & Trademark Office	ATTY. DOCKETT NO. SWA4338P0090US	SERIAL NO. 10/089,710
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Ray C.J. Chiu et al.	
		FILING DATE April 2, 2002	GROUP

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
	AA	5,486,359	Jan. 23, 1996	Caplan AI et al.			Feb. 8 1994
	AB	5,736,396	Apr. 7, 1998	Bruder et al.			Jan. 24, 1995
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED

NOV 05 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		Document number	Date	Country	Class	Subclass	Translation
	AL	wo 99/03937	Jan. 28, 1999	PCT			No
	AM						
	AN						
	AO						
	AP						
	AQ						

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	✓	L'enfant, C: Fixing the failing heart. Circulation 1997; 95:771-772
	✓	Olivetti G, Abbi R, Quaini F, et al.: Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-1141
	✓	Chiu RC-J, Zibaitis A, Kao RL: Cellular cardiomyoplasty: Myocardial regeneration with satellite cell implantation. Ann Thorac Surg 1995; 60:12-18
	✓	Soonpaa MH, Koh GY, Klug MG, et al.: Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science 1994; 264: 98-101
	✓	Klug M.G., Soonpaa M.H., Koh G.Y., Field L.J. Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J. Clin. Invest. 1996; 98:216-24
	✓	Li RK, Jia ZQ, Weisel RD et al. Cardiomyocyte transplantation improves heart function. Ann. Thor. Surg. 1996; 62:654-660